Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction: Multimodal treatments for patients with locally advanced synchronous esophageal and head and neck cancer.

International journal of clinical oncology·2026
Same author

Management Strategies for Disappearing Colorectal Liver Metastases After Systemic Chemotherapy: Long-Term Outcomes and Preoperative Prediction of 'True Complete Response'.

Annals of gastroenterological surgery·2026
Same author

Circulating Tumor DNA Status and Adjuvant Chemotherapy in Resected Colorectal Liver Metastases.

JAMA oncology·2026
Same author

Mapping the anatomical landscape of colorectal tumours: Location-specific efficacy of anti-epidermal growth factor receptor antibodies: Pooled analysis of randomised trials.

European journal of cancer (Oxford, England : 1990)·2026
Same author

Post-adjuvant chemotherapy in ctDNA-positive patients with resected colorectal cancer: a randomized phase 3 trial.

Nature medicine·2026
Same author

Impact of prior nivolumab on treatment outcomes of taxane plus ramucirumab in advanced gastric cancer.

Japanese journal of clinical oncology·2026

Related Experiment Video

Updated: Jul 13, 2026

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

[Bevacizumab (Avastin)].

Kentaro Yamazaki1, Takayuki Yoshino, Narikazu Boku

  • 1Division of Gastrointestinal Oncology and Endoscopy, Shizuoka Cancer Center, Japan.

Gan to Kagaku Ryoho. Cancer & Chemotherapy
|August 10, 2007
PubMed
Summary

Bevacizumab (Avastin) targets vascular endothelial growth factor (VEGF) to inhibit cancer angiogenesis. Clinical trials show it improves survival when added to chemotherapy for certain cancers, with acceptable toxicity.

Area of Science:

  • Oncology
  • Molecular Biology

Background:

  • Angiogenesis, the formation of new blood vessels, is critical for tumor growth and metastasis.
  • Vascular Endothelial Growth Factor (VEGF) is a key regulator of angiogenesis, and its overexpression is common in human cancers.
  • Increased VEGF expression correlates with poor patient outcomes, including recurrence, metastasis, and mortality.

Purpose of the Study:

  • To evaluate the efficacy and safety of Bevacizumab (Avastin) in Japanese patients with unresectable colorectal cancer.
  • To understand the clinical utility of Bevacizumab in combination with 5-fluorouracil-based chemotherapy.

Main Methods:

  • Review of pivotal Phase III clinical trials evaluating Bevacizumab in solid tumors.
  • Analysis of regulatory approvals by the United States Food and Drug Administration (FDA) and the Japanese Ministry of Health, Labour and Welfare (MHLW).

More Related Videos

Three-dimensional Angiogenesis Assay System using Co-culture Spheroids Formed by Endothelial Colony Forming Cells and Mesenchymal Stem Cells
09:24

Three-dimensional Angiogenesis Assay System using Co-culture Spheroids Formed by Endothelial Colony Forming Cells and Mesenchymal Stem Cells

Published on: September 18, 2019

Cerenkov Luminescence Imaging (CLI) for Cancer Therapy Monitoring
08:45

Cerenkov Luminescence Imaging (CLI) for Cancer Therapy Monitoring

Published on: November 13, 2012

Related Experiment Videos

Last Updated: Jul 13, 2026

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

Three-dimensional Angiogenesis Assay System using Co-culture Spheroids Formed by Endothelial Colony Forming Cells and Mesenchymal Stem Cells
09:24

Three-dimensional Angiogenesis Assay System using Co-culture Spheroids Formed by Endothelial Colony Forming Cells and Mesenchymal Stem Cells

Published on: September 18, 2019

Cerenkov Luminescence Imaging (CLI) for Cancer Therapy Monitoring
08:45

Cerenkov Luminescence Imaging (CLI) for Cancer Therapy Monitoring

Published on: November 13, 2012

  • Examination of Bevacizumab's approved dosage and administration schedule for colorectal cancer in Japan.

    • Main Results:

    • Bevacizumab, a monoclonal antibody targeting VEGF, has demonstrated survival benefits when combined with conventional chemotherapy in various solid tumors.
    • FDA and MHLW approvals support Bevacizumab's use in unresectable colorectal cancer and non-squamous, non-small cell lung cancer.
    • Japanese approval specifies Bevacizumab in combination with 5-fluorouracil chemotherapy at 5 or 10 mg/kg every 14 days.

    Conclusions:

    • Bevacizumab offers a survival advantage for patients with unresectable colorectal cancer when added to chemotherapy.
    • Understanding the efficacy and safety profile of Bevacizumab is crucial for its effective clinical application in Japan.
    • The established dosing and administration regimens provide a basis for clinical practice.